<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1201" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="837" end="840"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="886" end="895"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="Arsenic trioxide (ATO) is synergistic with ascorbic acid (AA) and melphalan&#13;&#10;against myeloma both in vitro and in vivo. The aim of this randomized phase II&#13;&#10;trial was to determine the safety and efficacy of a combination of ATO,&#13;&#10;melphalan, and AA as preparative regimen in 48 patients undergoing autologous&#13;&#10;hematopoietic stem cell transplantation (ASCT) for multiple myeloma (MM).&#13;&#10;Forty-eight patients received melphalan 200 mg/m2 i.v. over 2 days and AA 1000 mg&#13;&#10;i.v. over 7 days in 3 treatment arms: no ATO (arm 1), ATO 0.15 mg/kg i.v. x 7&#13;&#10;days (arm 2), and ATO 0.25 mg/kg i.v. x 7 days (arm 3). No dose-limiting&#13;&#10;toxicity, engraftment failure, or nonrelapse mortality (NRM) was seen in the&#13;&#10;first 100 days post-ASCT. Complete responses (CR) were seen in 12 of 48 patients &#13;&#10;(25%), with an overall response rate (ORR = CR + PR) of 85%. Median&#13;&#10;progression-free survival (PFS) was 25 months; median overall survival (OS) has&#13;&#10;not yet been reached. There was no significant difference in CR, PFS, or OS among&#13;&#10;the 3 treatment arms, and no adverse effect of ATO on melphalan pharmacokinetics.&#13;&#10;Addition of ATO + AA to high-dose melphalan is safe and well tolerated as a&#13;&#10;preparative regimen for MM."/>
    <cas:View sofa="6" members="1 13 17"/>
</xmi:XMI>
